Cytokinetics to Join June Investor Conferences

Cytokinetics, Incorporated, based in South San Francisco, California, announced its participation in two significant investor conferences scheduled for June 2024. The company’s President and CEO, Robert I. Blum, along with Executive Vice President and Chief Commercial Officer, Andrew Callos, will represent the company at these events.

The first event is the Jefferies Global Healthcare Conference, where Blum and Callos will engage in a fireside chat on June 5, 2024, at 2:00 PM Eastern Time. This conference will take place at the New York Marriott Marquis Hotel in New York City. The second event is the 45th Annual Goldman Sachs Healthcare Conference, scheduled for June 10, 2024, at 11:20 AM Eastern Time at the Loews Miami Beach Hotel in Miami Beach, Florida. Both events will be accessible via live webcasts through the Investors & Media section of the Cytokinetics website. The replays of these webcasts will be available on the website for 90 days after the events.

Cytokinetics is a late-stage biopharmaceutical company specializing in cardiovascular therapeutics. Their focus is on pioneering muscle activators and inhibitors to treat serious conditions involving compromised cardiac muscle performance. The company is recognized for its expertise in muscle biology and performance mechanics. They are currently advancing several promising drug candidates designed to enhance myocardial muscle function and contractility.

One of Cytokinetics’ leading drug candidates is aficamten, a cardiac myosin inhibitor. Positive results from the SEQUOIA-HCM Phase 3 clinical trial for obstructive hypertrophic cardiomyopathy (HCM) have prompted the company to prepare for regulatory submissions. Aficamten is also under evaluation in multiple Phase 3 trials: MAPLE-HCM (comparing aficamten as monotherapy to metoprolol in obstructive HCM patients), ACACIA-HCM (in non-obstructive HCM patients), CEDAR-HCM (targeting a pediatric population with obstructive HCM), and FOREST-HCM (an open-label extension study for HCM patients).

Apart from aficamten, Cytokinetics is developing omecamtiv mecarbil, a cardiac muscle activator aimed at treating heart failure. Another product in their pipeline is CK-586, a distinct cardiac myosin inhibitor for potentially treating heart failure with preserved ejection fraction (HFpEF). Additionally, CK-136, a cardiac troponin activator, is being developed for treating heart failure with reduced ejection fraction (HFrEF) and other heart failure types, including right ventricular failure due to impaired cardiac contractility.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!